Document is current
Any future updates will be listed below
-
Authors
Matsubara, Yuki
Bando, Hideaki https://orcid.org/0000-0001-5041-2765
Nakamura, Yoshiaki https://orcid.org/0000-0002-5241-6855
Misumi, Toshihiro
Ng, Dionne
Tajima, Eri
Pittell, Harlan
Ohtsu, Atsushi
Yoshino, Takayuki https://orcid.org/0000-0002-0489-4756
- License Information
-
More Information
Article History
Received: 5 June 2025
Revised: 10 October 2025
Accepted: 14 November 2025
First Online: 8 December 2025
Competing interests
: YM reports honoraria from MSD and Chugai Pharmaceutical. HB reports grants from Ono Pharmaceutical and GlaxoSmithKline; consulting fees from GxD and Guardant Health Japan; honoraria from Taiho Pharmaceutical, Ono Pharmaceutical and Guardant Health Japan. YN reports consulting fees from Guardant Health Pte Ltd., Natera Inc., Roche Ltd., Seagen Inc., Premo Partners Inc., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Co. Ltd., Exact Sciences Corporation and Gilead Sciences Inc.; honoraria from Guardant Health Pte Ltd., MSD K.K., Eisai Co. Ltd., Zeria Pharmaceutical Co. Ltd., Miyarisan Pharmaceutical Co. Ltd., Merck Biopharma Co. Ltd., CareNet Inc., Hisamitsu Pharmaceutical Co. Inc., Taiho Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Chugai Pharmaceutical Co. Ltd., Becton Dickinson and Company, and Guardant Health Japan Corp. TM reports consulting fees from Takeda Pharmaceutical Co., Ltd., and honoraria from Miyarisan, Boston Medical Sciences, and Anaut Inc. DN, HP and ET report employment at Flatiron Health Inc., an independent member of the Roche Group, and stock ownership in Roche. ET also reports being a board member of Flatiron Health K.K. AO reports honoraria from Chugai Pharmaceutical Co. Ltd. and Ono Pharmaceutical Co. Ltd. TY reports grants from Bristol-Myers Squibb K.K., Caris MPI Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Exact Sciences Corporation, FALCO biosystems Ltd., Medical & Biological Laboratories Co. Ltd., Merus N.V., Miyarisan Pharmaceutical Co. Ltd., MSD K.K., Natera Inc., Nippon Boehringer Ingelheim Co. Ltd., Ono Pharmaceutical Co. Ltd., Pfizer Japan Inc., Sysmex Corp., Taiho Pharmaceutical Co. Ltd. and Takeda Pharmaceutical Co. Ltd.; consulting fees from Sumitomo Corp.; honoraria from Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Merck Biopharma Co. Ltd. and Ono Pharmaceutical Co. Ltd.
: The Institutional Review Board of the National Cancer Center Hospital East (2024-031) approved this study and waived the requirement for informed consent due to the observational retrospective study design, with an opportunity to opt out provided on the institution’s website. All procedures were performed in accordance with the principles of the Declaration of Helsinki.
